Somalogic | GenomeWeb

Somalogic

The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.  

The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.

The company this week published a study in JAMA describing the panel, which is intended for assessing the risk of adverse events in coronary heart disease patients.

The firm said it will use the funds to support development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.

While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

Investigators from SomaLogic and elsewhere found proteins whose expression levels vary in Duchenne muscular dystrophy, often in conjunction with patients' age.

NEW YORK (GenomeWeb) – In a notice filed on Friday with the US Securities and Exchange Commission, Somalogic disclosed that it has raised $16.5 million.
According to the SEC document, the sale took place on Oct. 17 with equity going to two unidentified investors.

NEW YORK (GenomeWeb) – With new installations and rapidly growing revenues, Somalogic's SOMAscan platform is becoming a significant player in the protein biomarker discovery service space.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.